EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Xeris Biopharma Holdings's Enterprise Value is $416.2 Mil.
Xeris Biopharma Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-49.3 Mil. Therefore, Xeris Biopharma Holdings's EV-to-FCF for today is -8.44.
The historical rank and industry rank for Xeris Biopharma Holdings's EV-to-FCF or its related term are showing as below:
XERS'
s EV-to-FCF Range Over the Past 10 Years
Min: -12.2 Med: -2.3 Max: 1.12
Current: -8.44
During the past 8 years, the highest EV-to-FCF of Xeris Biopharma Holdings was 1.12. The lowest was -12.20. And the median was -2.30.
XERS's EV-to-FCF is ranked worse than 100% of 391
companies
in the Biotechnology industry
Industry Median: 4.47
vs XERS: -8.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xeris Biopharma Holdings's EV-to-FCF
For the Biotechnology subindustry, Xeris Biopharma Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's EV-to-FCF falls into.
Xeris Biopharma Holdings's current Enterprise Value is $416.2 Mil.
Xeris Biopharma Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Xeris Biopharma Holdings's PE Ratio for today is calculated as:
Xeris Biopharma Holdings's share price for today is $1.75.
Xeris Biopharma Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.440.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Xeris Biopharma Holdings EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Xeris Biopharma Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Xeris Biopharma Holdings (Xeris Biopharma Holdings) Business Description
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XERS has been successfully added to your 